133 related articles for article (PubMed ID: 37849604)
1. Transient Intraocular Pressure Fluctuations After Intravitreal Bevacizumab Injection in Proliferative Diabetic Retinopathy Patients: A Prospective Study.
Luqman F; Bibi H; Mukhtar M; Zafar F; Ahmed H; Khizer MA; Gul N
Cureus; 2023 Sep; 15(9):e45371. PubMed ID: 37849604
[TBL] [Abstract][Full Text] [Related]
2. Short-term intraocular pressure changes after intravitreal injection of bevacizumab in diabetic retinopathy patients.
Farhood QK; Twfeeq SM
Clin Ophthalmol; 2014; 8():599-604. PubMed ID: 24707164
[TBL] [Abstract][Full Text] [Related]
3. Short-term intraocular pressure changes after intravitreal injection of bevacizumab for retinopathy of prematurity.
Kato A; Okamoto Y; Okamoto F; Saito M; Miyazono Y; Oshika T
Jpn J Ophthalmol; 2019 May; 63(3):262-268. PubMed ID: 30825009
[TBL] [Abstract][Full Text] [Related]
4. Comparison of before versus after intravitreal bevacizumab injection, growth factor levels and fibrotic markers in vitreous samples from patients with proliferative diabetic retinopathy.
Ozer F; Tokuc EO; Albayrak MGB; Akpinar G; Kasap M; Karabas VL
Graefes Arch Clin Exp Ophthalmol; 2022 Jun; 260(6):1899-1906. PubMed ID: 35028761
[TBL] [Abstract][Full Text] [Related]
5. Surgical Treatment of Neovascular Glaucoma Secondary to Proliferative Diabetic Retinopathy in Japanese Patients without the Use of Glaucoma Drainage Devices.
Takeuchi M; Kanda T; Harimoto K; Sora D; Okazawa R; Sato T
J Clin Med; 2024 May; 13(11):. PubMed ID: 38892963
[No Abstract] [Full Text] [Related]
6. Panretinal photocoagulation versus panretinal photocoagulation plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy.
Zhou AY; Zhou CJ; Yao J; Quan YL; Ren BC; Wang JM
Int J Ophthalmol; 2016; 9(12):1772-1778. PubMed ID: 28003978
[TBL] [Abstract][Full Text] [Related]
7. Preoperative Timing of Intravitreal Bevacizumab Injection for Proliferative Diabetic Retinopathy Patients.
Feng J; Li B; Wen J; Jiang Y
Ophthalmic Res; 2018; 60(4):250-257. PubMed ID: 30380554
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bevacizumab.
Ma Y; Zhang Y; Zhao T; Jiang YR
Am J Ophthalmol; 2012 Feb; 153(2):307-313.e2. PubMed ID: 21982107
[TBL] [Abstract][Full Text] [Related]
9. Effect of prior glaucoma surgery on intraocular pressure immediately after anti-vascular endothelial growth factor injection.
Lam J; Luttrell I; Ding L; Rezaei K; Chao JR; Chee Y; Olmos De Koo LC; Wen JC
Graefes Arch Clin Exp Ophthalmol; 2019 Nov; 257(11):2489-2494. PubMed ID: 31388743
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases.
Wakabayashi T; Oshima Y; Sakaguchi H; Ikuno Y; Miki A; Gomi F; Otori Y; Kamei M; Kusaka S; Tano Y
Ophthalmology; 2008 Sep; 115(9):1571-80, 1580.e1-3. PubMed ID: 18440643
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of prophylactic intravitreal bevacizumab injection to proliferative diabetic retinopathy patients with elevated preoperative intraocular VEGF in preventing complications after vitrectomy.
Tsubota K; Usui Y; Wakabayashi Y; Suzuki J; Ueda S; Goto H
Clin Ophthalmol; 2019; 13():1063-1070. PubMed ID: 31303746
[TBL] [Abstract][Full Text] [Related]
12. Surgical outcome of intravitreal bevacizumab and filtration surgery in neovascular glaucoma.
Kitnarong N; Chindasub P; Metheetrairut A
Adv Ther; 2008 May; 25(5):438-43. PubMed ID: 18425438
[TBL] [Abstract][Full Text] [Related]
13. Ghost cell glaucoma after intravitreous injection of ranibizumab in proliferative diabetic retinopathy.
Xu J; Zhao M; Li JP; Liu NP
BMC Ophthalmol; 2020 Apr; 20(1):149. PubMed ID: 32295566
[TBL] [Abstract][Full Text] [Related]
14. Influence of preoperative intravitreal bevacizumab on visual function in eyes with proliferative diabetic retinopathy.
Ushida H; Kachi S; Asami T; Ishikawa K; Kondo M; Terasaki H
Ophthalmic Res; 2013; 49(1):30-6. PubMed ID: 23038607
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal bevacizumab alone or combined with 1 mg triamcinolone in diabetic macular edema: a randomized clinical trial.
Riazi-Esfahani M; Riazi-Esfahani H; Ahmadraji A; Karkhaneh R; Mahmoudi A; Roohipoor R; Ghasemi F; Yaseri M
Int Ophthalmol; 2018 Apr; 38(2):585-598. PubMed ID: 28349504
[TBL] [Abstract][Full Text] [Related]
16. Effects of intravitreal injection of bevacizumab with or without anterior chamber paracentesis on intraocular pressure and peripapillary retinal nerve fiber layer thickness: a prospective study.
Soheilian M; Karimi S; Montahae T; Nikkhah H; Mosavi SA
Graefes Arch Clin Exp Ophthalmol; 2017 Sep; 255(9):1705-1712. PubMed ID: 28616715
[TBL] [Abstract][Full Text] [Related]
17. Short-term intraocular pressure changes after intravitreal injection of bevacizumab.
Hollands H; Wong J; Bruen R; Campbell RJ; Sharma S; Gale J
Can J Ophthalmol; 2007 Dec; 42(6):807-11. PubMed ID: 18026202
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy.
Moradian S; Ahmadieh H; Malihi M; Soheilian M; Dehghan MH; Azarmina M
Graefes Arch Clin Exp Ophthalmol; 2008 Dec; 246(12):1699-705. PubMed ID: 18696095
[TBL] [Abstract][Full Text] [Related]
19. The early effects of intravitreal anti vascular endothelial growth factor agents on intraocular pressure and central corneal thickness.
Omay E; Elgin U; Sen E; Yilmazbas P
Int Ophthalmol; 2016 Oct; 36(5):665-70. PubMed ID: 26780098
[TBL] [Abstract][Full Text] [Related]
20. Short-Term Visual Acuity and Intraocular Pressure Changes and Their Correlation after Anti-Vascular Endothelial Growth Factor Injection.
Lim HB; Kim MS; Jo YJ; Kim JY
Ophthalmologica; 2016; 236(1):36-42. PubMed ID: 27073842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
